Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: Epicenter who wrote (1075)	2/3/1999 5:20:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 2539

Epicenter, it's from the Merrill Lynch report: Message 7631351 Our revenue estimates for the product are $650 million in 1999 and $900 million in 2000. Pfizer will book its share of profits in its Alliance Revenue line as it does for Lipitor and Aricept currently. We are assuming alliance revenue from Celebrex of $77 million and $113 million for 1999 and 2000, respectively. I just do a calculation and came up with the percentage cut. Granted, this is only Merrill's assumption, and I'm also "assuming" that Merrill Lynch's analyst has his source. Anthony